Literature DB >> 11572030

Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group.

P Icard1, P Goudet, C Charpenay, B Andreassian, B Carnaille, Y Chapuis, P Cougard, J F Henry, C Proye.   

Abstract

Because of the rarity of adrenocortical carcinoma, survival rates and the prognosis for patients who have undergone operation are not well known. The purpose of the French Association of Endocrine Surgery was to evaluate these factors over an 18-year period. A trend study was associated to assess changes in the clinical and biochemical presentations as well as the surgical evolution. A total of 253 patients (158 women, 95 men) with a mean age of 47 years were included. Cushing syndrome was the main clinical presentation (30%), and hormonal studies revealed secreting tumors in 66% of the cases. Altogether, 72% (n = 182) of patients underwent resection for cure, and 41.5% (n = 105) of them had an extensive resection because of metastatic cancer. A lymphadenectomy was performed in 32.5% (n = 89) of the cases. The operative mortality was 5.5% (n = 14). Patients were given mitotane as adjuvant therapy in 53.8% of the cases (n = 135). The results of staging were stage I in 16 patients (6.3%), stage II (local disease) in 126 patients (49.8%), stage III (locoregional disease) in 57 patients (22.5%), and stage IV (metastases) in 54 patients (21.3%). Neither tumor staging nor the rate of curative surgery changed during the study period. More subcostal incisions were performed, and the use of mitotane increased significantly. The 5-year actuarial survival rates were 38% overall, 50% in the curative group, 66% for stage I, 58% for stage II, 24% for stage III, and 0% for stage IV. Multivariate analysis showed that mitotane benefited only the group of patients not operated on for cure. A better prognosis was found in patients operated on after 1988 (p = 0.04), in those with precursor-secreting tumors (p = 0.005), and in those at local stages of the disease (p = 0.0003). Thus mitotane benefited only patients not operated on for cure. Curative resection, precursor secretion, recent diagnosis, and local stage were favorably associated with survival.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11572030     DOI: 10.1007/s00268-001-0047-y

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  24 in total

Review 1.  CLINICAL AND PATHOPHYSIOLOGIC ASPECTS OF ADRENOCORTICAL CARCINOMA.

Authors:  M B LIPSETT; R HERTZ; G T ROSS
Journal:  Am J Med       Date:  1963-09       Impact factor: 4.965

Review 2.  Diagnosis and treatment of functioning and nonfunctioning adrenocortical neoplasms including incidentalomas.

Authors:  N W Thompson; P S Cheung
Journal:  Surg Clin North Am       Date:  1987-04       Impact factor: 2.741

Review 3.  The risk of determining risk with multivariable models.

Authors:  J Concato; A R Feinstein; T R Holford
Journal:  Ann Intern Med       Date:  1993-02-01       Impact factor: 25.391

4.  The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring.

Authors:  H van Slooten; A J Moolenaar; A P van Seters; D Smeenk
Journal:  Eur J Cancer Clin Oncol       Date:  1984-01

5.  Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection.

Authors:  L E Harrison; P B Gaudin; M F Brennan
Journal:  Arch Surg       Date:  1999-02

6.  Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer.

Authors:  R Vassilopoulou-Sellin; V F Guinee; M J Klein; S H Taylor; K R Hess; P N Schultz; N A Samaan
Journal:  Cancer       Date:  1993-05-15       Impact factor: 6.860

7.  Adrenocortical carcinoma.

Authors:  K Cohn; L Gottesman; M Brennan
Journal:  Surgery       Date:  1986-12       Impact factor: 3.982

8.  Adrenal cortical carcinoma--a continuing challenge.

Authors:  D J Henley; J A van Heerden; C S Grant; J A Carney; P C Carpenter
Journal:  Surgery       Date:  1983-12       Impact factor: 3.982

9.  An eleven-year experience with adrenocortical carcinoma.

Authors:  R F Pommier; M F Brennan
Journal:  Surgery       Date:  1992-12       Impact factor: 3.982

10.  Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy.

Authors:  J P Luton; S Cerdas; L Billaud; G Thomas; B Guilhaume; X Bertagna; M H Laudat; A Louvel; Y Chapuis; P Blondeau
Journal:  N Engl J Med       Date:  1990-04-26       Impact factor: 91.245

View more
  142 in total

Review 1.  Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011?

Authors:  E Baudin; S Leboulleux; A Al Ghuzlan; C Chougnet; J Young; D Deandreis; F Dumont; F Dechamps; C Caramella; P Chanson; E Lanoy; I Borget; M Schlumberger
Journal:  Horm Cancer       Date:  2011-12       Impact factor: 3.869

Review 2.  FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma.

Authors:  Désirée Deandreis; Sophie Leboulleux; Caroline Caramella; Martin Schlumberger; Eric Baudin
Journal:  Horm Cancer       Date:  2011-12       Impact factor: 3.869

Review 3.  Management of adjuvant mitotane therapy following resection of adrenal cancer.

Authors:  M Terzolo; A Ardito; B Zaggia; F Laino; A Germano; S De Francia; F Daffara; A Berruti
Journal:  Endocrine       Date:  2012-06-17       Impact factor: 3.633

4.  Pulmonary resection for metastatic adrenocortical carcinoma: the National Cancer Institute experience.

Authors:  Clinton D Kemp; R Taylor Ripley; Aarti Mathur; Seth M Steinberg; Dao M Nguyen; Tito Fojo; David S Schrump
Journal:  Ann Thorac Surg       Date:  2011-10       Impact factor: 4.330

Review 5.  Multi-organ resection for locally advanced adrenocortical cancer: surgical strategy and literature review.

Authors:  F Guida; M Clemente; L Valvano; C Napolitano
Journal:  G Chir       Date:  2015 Sep-Oct

6.  Adrenocortical carcinoma with inferior vena cava tumour thrombus: multidetector CT (MDCT) evaluation and management.

Authors:  Priyank Yadav; Sohrab Arora; Devarshi Srivastava; Hira Lal
Journal:  BMJ Case Rep       Date:  2015-12-01

Review 7.  5th International ACC Symposium: Old Syndromes with New Biomarkers and New Therapies with Old Medications.

Authors:  Sarika N Rao; Mouhammed Amir Habra
Journal:  Horm Cancer       Date:  2015-12-10       Impact factor: 3.869

Review 8.  [Surgical strategies for non-metastatic adrenocortical carcinoma].

Authors:  N Rayes; M Quinkler; T Denecke
Journal:  Chirurg       Date:  2018-06       Impact factor: 0.955

9.  Functional Albumin Nanoformulations to Fight Adrenocortical Carcinoma: a Redox-Responsive Approach.

Authors:  Manuela Curcio; Paola Avena; Giuseppe Cirillo; Ivan Casaburi; Umile Gianfranco Spizzirri; Fiore Pasquale Nicoletta; Francesca Iemma; Vincenzo Pezzi
Journal:  Pharm Res       Date:  2020-02-14       Impact factor: 4.200

10.  [Diagnostic pitfalls with Cushing's syndrome].

Authors:  W Hunger-Battefeld; M Gajda; A Hansch; A Mandecka; U A Müller; G Wolf
Journal:  Internist (Berl)       Date:  2010-03       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.